Panomifene
Panomifene (INN) (former developmental code names GYKI-13504, EGIS-5650) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen that was under development as an antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer but was not marketed.[1][2][3][4][5][6] It reached phase II clinical trials before development was terminated.[2] The drug was described in 1981.[1]
 | |
| Clinical data | |
|---|---|
| Other names | GYKI-13504; EGIS-5650 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H24F3NO2 |
| Molar mass | 427.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 930–. ISBN 978-1-4757-2085-3.
- http://adisinsight.springer.com/drugs/800002425
- Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 60–. ISBN 978-3-642-58616-3.
- Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 292–. ISBN 978-3-642-60107-1.
- Pierre H. Dixneuf; Christian Bruneau (18 October 2014). Ruthenium in Catalysis. Springer. pp. 385–. ISBN 978-3-319-08482-4.
- Borvendég J, Hermann I, Csuka O (1996). "Antiestrogens, antiandrogens". Acta Physiol Hung. 84 (4): 405–6. PMID 9328614.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.